The stock price of ORIC Pharmaceuticals Inc (NASDAQ: ORIC) has surged by 2.98 when compared to previous closing price of 9.39, but the company has seen a 5.57% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-06 that SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 2, 2025 (the “Grant Date”), ORIC granted a total of 39,100 non-qualified stock options and 6,500 restricted stock units to three new non-executive employees who began their employment with ORIC in May 2025.
Is It Worth Investing in ORIC Pharmaceuticals Inc (NASDAQ: ORIC) Right Now?
Company’s 36-month beta value is 1.49.Analysts have differing opinions on the stock, with 10 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ORIC is 39.91M, and currently, short sellers hold a 33.45% ratio of that floaft. The average trading volume of ORIC on June 13, 2025 was 1.15M shares.
ORIC’s Market Performance
ORIC’s stock has seen a 5.57% increase for the week, with a 82.11% rise in the past month and a 25.58% gain in the past quarter. The volatility ratio for the week is 4.18%, and the volatility levels for the past 30 days are at 7.49% for ORIC Pharmaceuticals Inc The simple moving average for the last 20 days is 29.42% for ORIC stock, with a simple moving average of 15.53% for the last 200 days.
Analysts’ Opinion of ORIC
Many brokerage firms have already submitted their reports for ORIC stocks, with Wells Fargo repeating the rating for ORIC by listing it as a “Overweight.” The predicted price for ORIC in the upcoming period, according to Wells Fargo is $20 based on the research report published on October 31, 2024 of the previous year 2024.
Stifel, on the other hand, stated in their research note that they expect to see ORIC reach a price target of $20. The rating they have provided for ORIC stocks is “Buy” according to the report published on September 06th, 2024.
ORIC Trading at 59.88% from the 50-Day Moving Average
After a stumble in the market that brought ORIC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.08% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ORIC starting from Piscitelli Dominic, who sale 2,976 shares at the price of $10.01 back on Jun 11 ’25. After this action, Piscitelli Dominic now owns 102,117 shares of ORIC Pharmaceuticals Inc, valued at $29,777 using the latest closing price.
Piscitelli Dominic, the Chief Financial Officer of ORIC Pharmaceuticals Inc, sale 324 shares at $10.00 during a trade that took place back on Jun 10 ’25, which means that Piscitelli Dominic is holding 105,093 shares at $3,240 based on the most recent closing price.
Stock Fundamentals for ORIC
Current profitability levels for the company are sitting at:
- -275.09 for the present operating margin
- 0.49 for the gross margin
The net margin for ORIC Pharmaceuticals Inc stands at -249.26. The total capital return value is set at -0.65. Equity return is now at value -48.45, with -44.76 for asset returns.
Currently, EBITDA for the company is -126.74 million with net debt to EBITDA at 0.34. When we switch over and look at the enterprise to sales, we see a ratio of 1197.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.00.
Conclusion
In a nutshell, ORIC Pharmaceuticals Inc (ORIC) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
